In the News

28bio Launches CNS-3D Alzheimer’s Model to Predict Therapeutic Efficacy The CNS-3D Induced Alzheimer’s Model is a brain organoid assay enabling researchers to evaluate whether therapeutic candidates can reduce or prevent disease progression in patients.

In the News

April 2, 2026

min read

Accelerating Organoid Adoption Set to Transform Cancer Drugs When asked about the biggest obstacles preventing organoids from reaching their full potential, Alif Saleh, CEO of 28bio, emphasizes that adoption, not technology, is the primary hurdle, particularly in drug discovery, where a staggering 95% failure rate is accepted as the norm.

March 23, 2026

min read

28bio’s Endurance Study Meets Primary Endpoint, Showing CNS-3D Brain Organoids Predict Clinical Seizure Liability 28bio reports Endurance Study results showing brain organoids predict clinical seizure liability with 83% sensitivity and 89% specificity.

June 9, 2025

min read

The Clumps of Brain Cells That Can Play Pac-Man What they mean for medicine and perhaps the future of AI data centers.

More News

In the News

28bio Launches CNS-3D Inflammatory Organoids to Predict Anti-inflammatory Therapeutic Efficacy

The only assay-ready immunocompetent 3D brain organoid model incorporating microglia for studies of neuroinflammatory mechanisms and drug efficacy

Spotlights

February 5, 2026

min read

Modeling Myelination and Therapeutic Response in Demyelinating Disorders

CNS-3D and PNS-3D organoids support authentic myelin formation and enable high-throughput measurement of myelination for therapeutic screening.

February 5, 2026

min read

Organoid Intelligence Offers New Evidence of Learning-related Activity in Human Neural Tissue

Human-derived neural networks can exhibit measurable markers of learning and memory processes.

December 5, 2025

min read

Organoid Neurotoxicity Testing Embraced by FDA and NIH

Scientists and regulators have long acknowledged the weaknesses in traditional methods used to identify drugs that may harm the central nervous system.

Subscribe to 28bioNEWS

28bioNEWS is a monthly market intelligence briefing built for those shaping the future of drug discovery and development.

Learn More

In the News

28bio Launches CNS-3D Myelinated Organoids to Predict Therapeutic Efficacy

CNS-3D Myelinated Organoids are designed to quantify drug-induced demyelination, observe natural remyelination, and evaluate therapeutic strategies for myelin repair, capturing both injury and recovery within the same biological context.

Case Studies

Case Study

min read

Takeda Implements CNS-3D Organoids for Preclinical Neurotoxicity Assessment

CNS-3D organoids provide a human-relevant context for the detection of compound-induced neurotoxicity, supports multiplexed endpoint analysis, and reduces reliance on animal testing.

Takeda’s Validated Method for CNS Safety

Learn how CNS-3D brain organoids deliver 7.4× better clinical predictivity than animal models in this on-demand webinar with Takeda’s Investigative Toxicology team.

Learn More